AzTrials
AzTrials

Septic ShockNCT07245550

Thyroid and Adrenal Disorders in ICU

An observational study of Septic Shock, run by Assiut University at 1 site in Egypt.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

A dysregulated host response to infection results in organ failure and sepsis, a potentially fatal illness. Sepsis killed about 11 million people worldwide in 2017 and had a death rate close to 20 % Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Septic Shock
What is being tested?
Blood sampling
How many people
200 participants
Where
1 siteEgypt
Study dates
1 Dec 2025to 1 Dec 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients with septic shock admitted at intensive care unit and their age is above 18 years old

Who may be able to join

  • All Patients who match the diagnostic criteria for sepsis/septic shock as stated
  • admitted in ICU

Who cannot join

  • Patients refuse to be enrolled in the study
  • Patients with previous endocrinal disorders.
  • Patients receiving corticosteroid or thyroid hormonal therapy.
  • Pregnancy or lactation.
  • Previous endocrinal gland surgery.
  • Individuals with pacing rhythms, bundle branch blocks (QRS interval >120 ms),

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Egypt1 site
  • Radwa mahmoud

    Asyut

    Assuit U Hospital

Other trials in Egypt

About this study

Official title: Thyroid and Adrenal Disorders in ICU Patients With Septic Shock

A dysregulated host response to infection results in organ failure and sepsis, a potentially fatal illness. Sepsis killed about 11 million people worldwide in 2017 and had a death rate close to 20 %

Read the detailed description

Sepsis syndromes span a clinical continuum with variable prognoses. Septic shock, the most severe complication of sepsis, carries high mortality. In response to an inciting agent, pro-inflammatory and anti-inflammatory arms of the immune system are activated in concert with the activation of monocytes, macrophages, and neutrophils that interact with the endothelium through pathogen recognition receptors to elaborate cytokines, proteases, kinins, reactive oxygen species, and nitric oxide .Sepsis syndromes caused by multidrug-resistant bacterial strains (methicillin-resistant Staphylococcus, vancomycin-resistant enterococci are on the rise with a current incidence of up to 25%; viruses and parasites cause far fewer cases and are identified in 2% to 4% of cases . It is a well-known fact that the thyroid gland plays an important role in regulating metabolism, growth, and development by secretion of hormones such as thyroxine (T4) and triiodothyronine (T3). In critical illness, changes occur in the hypothalamic-pituitary-thyroid (HPT) axis which leads to euthyroid sick syndrome or non-thyroidal illness syndrome (NTIS). This condition is characterized by decreased T3 levels, normal to low levels of T4, and normal to decreased thyroid-stimulating hormone (TSH) levels despite the absence of intrinsic thyroid disease in patients. The pathophysiology of NTIS involves alterations in thyroid hormone production, peripheral conversion of T4 to T3, and increased degradation of thyroid hormones. During critical illness, cytokines and inflammatory mediators such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) play a significant role in these hormonal changes. Reduced activity of deiodinases, enzymes responsible for the conversion of T4 to T3, further contributes to decreased T3 levels. Critical illness is associated with increased systemic cortisol availability, a vital part of the stress response. Stress can cause life-threatening adrenal crisis when a disease of the hypothalamic-pituitary-adrenal (HPA) axis is present and not adequately treated with stress doses of hydrocortisone. Hence understanding these changes is vital to improve prognosis in patients under intensive care. For instance, in the absence of adrenal insufficiency, stress doses of hydrocortisone can be used to reduce the high vasopressor need in patients suffering from septic shock .In response to stress, adrenal gland generates high levels of glucocorticoid (GC). We call this induced GC (IGC). Unfortunately, 25-60% of septic patients experience relative adrenal insufficiency (RAI). RAI is defined by impaired IGC production in response to stress, which is diagnosed by a delta total cortisol of < 9 μg/dL post-ACTH stimulation. Thus, understanding the endocrine changes and correction of these hormone levels as early as possible may reduce the hospitalization duration, thereby improving the prognosis of the patients. However, there is a lacuna in the literature regarding the level of these hormones at various timelines in critically ill patients classified according to the APACHE II classification in India. With the available data, we aimed to determine the thyroid and cortisol changes in acute severely ill patients and to assess their relationship with the severity of illness.

Conditions
Septic Shock
Being tested
Blood sampling
Keywords
septic shock
Medical subject headings
Shock, Septic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07245550
Study groupRoleWhat they receive
Patients with septic shock in the ICUBlood sampling for thyroid and adrenal hormones
Receives: Diagnostic Test: Blood sampling

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. serum Thyroid and adrenal hormones levels

    measurement of thyroid and adrenal hormones (TSH-FT3-FT4 - cortisol level ) will be measured by ELLISA technique in septic shock patients at ICU.

    Measured: 24 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Nov 2025
  2. Study start1 Dec 2025 (estimated)
  3. Primary completion1 Dec 2026 (estimated)
  4. Study completion1 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07245550
Sponsor's protocol ID
TAICU
Status last verified
Nov 2025
First submitted
26 Sep 2025
Last updated
24 Nov 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Septic Shock, run by Assiut University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 24 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Radwa M Elsayed, MB (01001673731 ext. 01001673731, Radwaamahmoud11@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

serum Thyroid and adrenal hormones levels (time frame: 24 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Nov 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in